首页> 外国专利> Methods for reducing the risk of an adverse dronedarone/calcium channel blockers interaction in a patient suffering from atrial fibrillation

Methods for reducing the risk of an adverse dronedarone/calcium channel blockers interaction in a patient suffering from atrial fibrillation

机译:降低房颤患者中决奈达隆/钙通道阻滞剂不良相互作用的风险的方法

摘要

#$%^&*AU2010202705A120120119.pdf#####21 METHOD FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / CALCIUM CHANNEL BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILLATION SANOFI-AVENTIS ABSTRACT The invention relates to a method for managing the risk of dronedarone /calcium channel blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a calcium channel blockers treatment, by performing the following steps: a- initiate calcium channel blockers treatment at a low dose; b- performing a electrocardiogram (ECG) verification of good tolerability; c- increase of calcium channel blockers dose only if results in step b) are satisfying.
机译:#$%^&* AU2010202705A120120119.pdf #####21减少不良无人机的风险的方法/患者患钙通道阻滞剂的相互作用心房颤动萨诺菲-安万提斯抽象本发明涉及一种控制决奈达隆/钙风险的方法使用决奈达隆或药学上可接受的盐进行通道阻滞剂相互作用对于阵发性或持续性房颤(AF)或房扑(AFL)的患者,鼻窦房颤/房颤近期发作及相关的心血管危险因素节律或谁会心动过缓以减少心血管疾病住院的风险,还希望通过执行以下操作来接受钙通道阻滞剂治疗的患者以下步骤:低剂量开始钙通道阻滞剂治疗;b-执行心电图(ECG)验证,具有良好的耐受性;c-仅当步骤b)中的结果令人满意时,才增加钙通道阻滞剂的剂量。

著录项

  • 公开/公告号AU2010202705A1

    专利类型

  • 公开/公告日2012-01-19

    原文格式PDF

  • 申请/专利权人 SANOFI-AVENTIS;

    申请/专利号AU2010202705A1

  • 发明设计人 RADZIK DAVIDE;GAUD CHRISTINE;

    申请日2010-06-29

  • 分类号A61P9/06;A61K31/343;

  • 国家 AU

  • 入库时间 2022-08-21 17:19:44

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号